Telos Capital Management Inc. Has $8.04 Million Stake in Johnson & Johnson (NYSE:JNJ)

Telos Capital Management Inc. lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 10.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,459 shares of the company's stock after selling 5,837 shares during the quarter. Telos Capital Management Inc.'s holdings in Johnson & Johnson were worth $8,036,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Round Rock Advisors LLC boosted its stake in shares of Johnson & Johnson by 1.9% in the 1st quarter. Round Rock Advisors LLC now owns 9,681 shares of the company's stock valued at $1,605,000 after purchasing an additional 179 shares during the last quarter. Allworth Financial LP lifted its stake in Johnson & Johnson by 1.8% in the first quarter. Allworth Financial LP now owns 329,321 shares of the company's stock valued at $51,022,000 after buying an additional 5,958 shares in the last quarter. Stonebrook Private Inc. lifted its position in shares of Johnson & Johnson by 3.0% in the first quarter. Stonebrook Private Inc. now owns 23,070 shares of the company's stock worth $3,826,000 after purchasing an additional 668 shares in the last quarter. Rock Point Advisors LLC lifted its position in shares of Johnson & Johnson by 2.1% in the first quarter. Rock Point Advisors LLC now owns 6,058 shares of the company's stock worth $1,005,000 after purchasing an additional 125 shares in the last quarter. Finally, Rogco LP lifted its position in shares of Johnson & Johnson by 1.1% in the first quarter. Rogco LP now owns 10,912 shares of the company's stock worth $1,810,000 after purchasing an additional 120 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $0.82 during trading on Friday, reaching $156.87. The company's stock had a trading volume of 7,866,488 shares, compared to its average volume of 8,077,942. The business's 50-day moving average price is $153.75 and its 200-day moving average price is $154.49. The firm has a market cap of $377.44 billion, a PE ratio of 17.45, a P/E/G ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.31%. Johnson & Johnson's payout ratio is presently 57.84%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JNJ. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Royal Bank Of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, June 5th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Morgan Stanley reiterated an "underperform" rating on shares of Johnson & Johnson in a report on Thursday. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.